Sandoz Drops Generic Mirapex Plans For Now

Law360, New York (July 30, 2010, 6:46 PM EDT) -- Sandoz Inc. has given up its fight to market a generic version of Boehringer Ingelheim International GmbH's Parkinson's drug Mirapex before Boehringer's patent on the drug expires in October in light of a preliminary injunction barring its proposed generic.

Sandoz filed a stipulation Wednesday in the U.S. District Court for the Middle District of Florida that it would not try to market generic Mirapex before the expiration of the patent.

The stipulation followed an order by Judge Timothy J. Corrigan at a hearing July 26 granting...
To view the full article, register now.